The estimated Net Worth of Hong Yu is at least $1.65 Milione dollars as of 7 December 2022. Mr Yu owns over 83,676 units of Biostage stock worth over $896,510 and over the last 6 years he sold BSTG stock worth over $599,957. In addition, he makes $157,950 as Pres at Biostage.
Sign up
Mr Hong BSTG stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Biostage stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 83,676 units of BSTG stock worth $599,957 on 7 December 2022.
The largest trade he's ever made was selling 83,676 units of Biostage stock on 7 December 2022 worth over $599,957. On average, Mr trades about 20,946 units every 273 days since 2018. As of 7 December 2022 he still owns at least 222,459 units of Biostage stock.
You can see the complete history of Mr Yu stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Yu Hong biography
Yu Hong is the Pres at Biostage.
What is the salary of Mr Hong?
As the Pres of Biostage, the total compensation of Mr Hong at Biostage is $157,950. There are 2 executives at Biostage getting paid more, with David Green having the highest compensation of $534,506.
How old is Mr Hong?
Mr Hong is 48, he's been the Pres of Biostage since . There are 5 older and 1 younger executives at Biostage. The oldest executive at Biostage, Inc. is James Shmerling, 63, who is the Director.
What's Mr Hong's mailing address?
Hong's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Insiders trading at Biostage
Over the last 9 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst e Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.
What does Biostage do?
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
What does Biostage's logo look like?
Complete history of Mr Yu stock trades at Biostage
Biostage executives and stock owners
Biostage executives and other stock owners filed with the SEC include:
-
David Green,
Director -
Dr. William L. Fodor Ph.D.,
Chief Scientific Officer -
Yu Hong,
Pres -
Thomas Robinson,
Independent Director -
James Shmerling,
Director -
Ting Li,
Director -
Harout DerSimonian,
Chief Scientific Officer -
James Mastridge,
Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer -
Hong Yu,
President -
Jason Jing Chen,
Chairman of the Board -
Dr. Shunfu Hu Ph.D.,
VP of Bus. Devel. & Operations -
Peter A. Pellegrino Jr.,
Interim VP of Fin. -
David Green,
CEO & Chairman -
Blaine H. Mc Kee,
Director -
Saverio La Francesca,
See Remarks -
John J Canepa,
Director -
Thomas Mc Naughton,
Chief Financial Officer -
John F Kennedy,
Director -
James Joseph Mc Gorry,
Chief Executive Officer -
William Fodor,
Chief Scientific Officer -
Herman Sanchez,
Director -
Xiaoyu Du,
10% owner -
Matthew D Dallas,
Director -
Wei Zhang,
Director -
Jeffrey E Young,
Director -
Peter M Chakoutis,
Vice President of Finance -
Ronald J Packard,
Director -
Capital Llc Dst,
10% owner -
Jing Chen,
-
Junli He,
CEO -
Joseph Luis Jr Damasio,
Chief Financial Officer